651734-55-3

Usage

Uses

Used in Organic Synthesis:
Methyl 2,6-difluoro-3,5-dimethoxybenzoate serves as a key intermediate in organic synthesis, contributing to the creation of a wide range of chemical compounds. Its unique structure allows for versatile reactions and modifications, making it a valuable component in the synthesis of various organic molecules.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, methyl 2,6-difluoro-3,5-dimethoxybenzoate is used as a reagent for the development of new drugs and materials. Its distinctive chemical properties make it a promising candidate for the synthesis of pharmaceutical compounds, potentially leading to the discovery of novel therapeutic agents.
Used in Research:
Methyl 2,6-difluoro-3,5-dimethoxybenzoate is also utilized in research settings to explore its properties and potential applications. Scientists and researchers employ methyl 2,6-difluoro-3,5-dimethoxybenzoate to investigate its chemical behavior, reactivity, and interactions with other molecules, which can contribute to a deeper understanding of its capabilities and uses in various fields.

Upstream product

• 67-56-1 methanol 
• 651734-56-4 2,6-difluoro-3,5-dimethoxybenzoic acid 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 

Downstream Products

• 1453208-75-7 5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrimidin-2-amine 
• 1453208-66-6 2-[4-({5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]pyrimidin-2-yl}amino)-1H-pyrazol-1-yl]ethanol 
• 1453208-09-7 5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine 
• 1890954-24-1 2,6-difluoro-3,5-dimethoxybenzene(meth)aldehyde 

Relevant academic research and scientific papers

COMPOUNDS FOR INHIBITING FGFR4

Provided herein are compounds which inhibit FGFR4, compositions thereof, methods of their preparation, and methods for treating disorders mediated by FGFR4 such as cancer.

HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

This disclosure relates to heterocyclics as selective inhibitors of the fibroblast growth factor receptor 4 (FGFR-4), in particular relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound.

Heterocyclic compound as FGFR inhibitor, synthesis method and applications thereof

The present invention discloses a heterocyclic compound as an FGFR inhibitor, and a synthesis method thereof, and applications of the heterocyclic compound in preparation of drugs for treating cancers. According to the present invention, the heterocyclic compound as the FGFR inhibitor or the pharmaceutically acceptable salt thereof has high FGFR inhibitory action, and the pharmaceutical composition prepared from the heterocyclic compound has good anticancer effect and wide application range.

FGFR4 INHIBITORS

Methods, compounds, pharmaceutical compositions, and methods of preparing medicaments for treating hepatocellular carcinoma having an altered FGFR4 and/or FGF19 status.

PHARMACEUTICAL COMPOSITION HAVING PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT

[Problem] A pharmaceutical composition for treating FGFR4-related cancer, FGF 19-related cancer, or FGF19 gene amplification-positive liver cancer is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory ac

Methods for detecting FGFR3/TACC3 fusion genes

[Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set,

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND

Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.

[4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS

The invention provides a novel class of compounds of the Formula (I): in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prev